Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...

AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

Protara applies modern science, manufacturing, and regulatory expertise to reimagine proven medicines and deliver new ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan ...

Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&D center and future U.K.

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

U.S. nonprofit Wellcome Leap is partnering with the Melinda French Gates-founded coalition Pivotal, raising $100 million to ...

The pause is the latest blow to the U.K.’s biotech industry, which is still reeling from Merck’s recently announced R&D exodus, including the cancellation of a 1 billion pound sterling London research ...

The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from ...